EarningsQ4 2026 Earnings Report
DE:RMY Q4 2026 EPS Results
Actual EPS€0.50
Consensus EPS€0.43
Beat/MissBeat by +€0.07
One Year Ago EPS€0.35
DE:RMY Q4 2026 Revenue Results
Actual Revenue€5.73B
Expected Revenue€5.74B
Beat/MissMissed by -€12.61M
YoY Revenue Growth-0.24%
Earnings Announcement Details
QuarterQ4 2026
Date08/26/2026
TimeAfter Close
Conference CallWednesday, August 26, 2026
DE:RMY Upcoming Earnings
Ramsay Health Care's next earnings date is estimated for March 3, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
DE:RMY Q4 2026 Earnings Call
0:00 / 0:00
Q4 2026 Earnings Slide Deck
Q4 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents strong operational and financial momentum driven by Australian transformation initiatives and Funding Group improvements — evidenced by double-digit underlying EBIT growth in Australia, broad regional EBIT growth, improved margins and cash generation, higher dividends, and successful cost and utilization measures. Offsetting these positives are notable challenges in Europe (Ramsay Santé funding headwinds and working capital/timing issues), restructure costs and demand weakness at Elysium, wage inflation pressures from multi-year EBAs, a remediation provision relating to a Fair Work decision, and increased interest costs. On balance the company demonstrates tangible progress on its strategic priorities and financial discipline while managing several region-specific headwinds.Company Guidance
Group Revenue and Profit Growth
Total revenue of $18.6 billion, up 4.2% year-over-year in constant currency; underlying EBIT increased 11.8% and underlying NPAT increased 22.9%; reported NPAT was $329 million.
Strong Australian Performance
Australia delivered 8% revenue growth and 11.2% underlying EBIT growth, with underlying EBIT margin up 30 basis points to 9.4%; surgical admissions +4.1%, medical admissions +3.2%, rehabilitation +3.8%; private admissions +2.8% and public admissions +9.5%.
Operational Improvements and Capacity Gains
Theatre utilization improved to 70% (from 69%) and 22 new theatres/procedure rooms were opened during the year (11 additional theatres/cath labs planned for FY27); increased robotics usage and 3.3% growth in admitting VMOs enabled by data insights and salesforce uplift.
Funding Group Financial Strength
Funding Group underlying NPAT grew 17.9% to $398.4 million with revenue +5.2% in constant currency; Funding Group ROCE increased to 14.8% (up 124 bps); Funding Group leverage reduced to 1.83x (well below target range) and interest cover strong at 8.94x; liquidity of $1.066 billion maintained.
Cash Generation and Capital Discipline
Free cash flow of $697 million (flat vs prior year) driven by improved operating cash flow (46% improvement in Funding Group) and disciplined development CapEx (group CapEx $734.2 million, down 6.1% in constant currency); Australia CapEx $365 million (below forecast).
Dividend Increase and Shareholder Returns
Final fully franked dividend of $0.485 per share (up 21.3%) and full-year dividend $0.91 per share (up 13.8%), representing a payout ratio of 60.3% of underlying earnings.
Elysium Turnaround Traction
Elysium delivered 43% growth in underlying EBIT, achieved positive cash flow through site/ward closures, cost reductions and a 4.4% average fee uplift; restructure actions reducing central and agency costs.
Progress on Strategic Initiatives and Separation
Acceleration of Australian transformation programs (Big 5 operations initiatives, procurement, revenue cycle/technology roadmap); proposed separation of Ramsay Santé progressing to shareholder vote in November 2026 to simplify portfolio and focus strategy.
DE:RMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed